|
PLUTO: A randomised phase II study of pazopanib versus paclitaxel in relapsed urothelial tumours. |
| |
|
Honoraria - Bristol-Myers Squibb; Novartis; Roche/Genentech |
Consulting or Advisory Role - Bristol-Myers Squibb; Genentech/Roche; Merck |
Research Funding - AstraZeneca/MedImmune; GlaxoSmithKline; Roche/Genentech |
| |
|
Consulting or Advisory Role - Astellas Pharma; Bayer; Pierre Fabre |
Research Funding - Boehringer Ingelheim; Janssen-Cilag; Pierre Fabre |
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Boehringer Ingelheim; Janssen-Cilag; MSD Oncology; Pfizer; Pierre Fabre; Roche |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Honoraria - Bayer; Sanofi |
Consulting or Advisory Role - Astellas Pharma; Bayer; Dendreon; Janssen; Pfizer; Sanofi |
Research Funding - AstraZeneca |
Travel, Accommodations, Expenses - Astellas Pharma; Janssen; Janssen; Novartis; Sanofi |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
Akhila Ganeshi Wimalasingham |
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |